A detailed history of Huntington National Bank transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Huntington National Bank holds 643 shares of BMRN stock, worth $52,938. This represents 0.0% of its overall portfolio holdings.

Number of Shares
643
Previous 111 479.28%
Holding current value
$52,938
Previous $10,000 460.0%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 03, 2024

BUY
$83.81 - $99.0 $44,586 - $52,668
532 Added 479.28%
643 $56,000
Q4 2023

Feb 07, 2024

BUY
$76.22 - $98.51 $3,506 - $4,531
46 Added 70.77%
111 $10,000
Q3 2023

Nov 08, 2023

SELL
$85.07 - $94.48 $2,722 - $3,023
-32 Reduced 32.99%
65 $5,000
Q2 2023

Aug 11, 2023

BUY
$86.68 - $100.3 $4,767 - $5,516
55 Added 130.95%
97 $8,000
Q1 2023

May 10, 2023

BUY
$87.74 - $117.27 $3,597 - $4,808
41 Added 4100.0%
42 $4,000
Q4 2022

Feb 09, 2023

SELL
$80.93 - $108.63 $890 - $1,194
-11 Reduced 91.67%
1 $0
Q3 2022

Nov 07, 2022

SELL
$82.16 - $96.94 $13,885 - $16,382
-169 Reduced 93.37%
12 $0
Q2 2022

Aug 09, 2022

BUY
$71.48 - $86.85 $12,080 - $14,677
169 Added 1408.33%
181 $14,000
Q4 2021

Jan 21, 2022

BUY
$71.72 - $91.47 $71 - $91
1 Added 9.09%
12 $0
Q1 2020

Apr 27, 2020

SELL
$71.37 - $96.85 $12,347 - $16,755
-173 Reduced 94.02%
11 $0
Q4 2019

Jan 17, 2020

BUY
$64.27 - $86.37 $7,969 - $10,709
124 Added 206.67%
184 $15,000
Q3 2019

Nov 01, 2019

BUY
$67.4 - $85.11 $3,302 - $4,170
49 Added 445.45%
60 $3,000
Q2 2019

Jul 23, 2019

SELL
$80.35 - $93.9 $6,428 - $7,512
-80 Reduced 87.91%
11 $0
Q1 2019

Apr 09, 2019

SELL
$84.2 - $98.62 $1,431 - $1,676
-17 Reduced 15.74%
91 $7,000
Q4 2018

Jan 28, 2019

SELL
$80.14 - $106.07 $78,216 - $103,524
-976 Reduced 90.04%
108 $9,000
Q3 2018

Oct 18, 2018

BUY
$93.92 - $105.72 $101,809 - $114,600
1,084 New
1,084 $105,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $15.3B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Huntington National Bank Portfolio

Follow Huntington National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Huntington National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Huntington National Bank with notifications on news.